ARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:

Similar documents
ARIC Manuscript Proposal #1377

ARIC Manuscript Proposal # 1518

ARIC Manuscript Proposal #1233. PC Reviewed: 4_/_10/07 Status: _A Priority: 2_ SC Reviewed: Status: Priority:

ARIC Manuscript Proposal # PC Reviewed: 05/12/09 Status: A Priority: 2 SC Reviewed: Status: Priority:

ARIC Manuscript Proposal #2099. PC Reviewed: 3/12/13 Status: A Priority: 2 SC Reviewed: Status: Priority:

ARIC Manuscript Proposal #1491. PC Reviewed: 03/17/09 Status: A Priority: 2 SC Reviewed: Status: Priority:

Epidemiologic Measure of Association

T. Suithichaiyakul Cardiomed Chula

Total risk management of Cardiovascular diseases Nobuhiro Yamada

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

Supplement materials:

ARIC Manuscript Proposal #2493. PC Reviewed: 2/10/15 Status: A Priority: 2 SC Reviewed: Status: Priority:

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

ARIC Manuscript Proposal #2426. PC Reviewed: 9/9/14 Status: A Priority: 2 SC Reviewed: Status: Priority:

Antihypertensive Trial Design ALLHAT

ARIC Manuscript Proposal # 947. PC Reviewed: 07/01/03 Status: A Priority: 2 SC Reviewed: 07/18/03 Status: A Priority: 2

SUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.

Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES

ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial

YOUNG ADULT MEN AND MIDDLEaged

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up

Supplementary Online Content

ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults

Correlation of novel cardiac marker

Does quality of life predict morbidity or mortality in patients with atrial fibrillation (AF)?

1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria

SUPPLEMENTAL MATERIAL. Supplemental Methods. Duke CAD Index

JUSTUS WARREN TASK FORCE MEETING DECEMBER 05, 2012

Egyptian Hypertension Guidelines

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Cardiovascular Diseases in CKD

HEART FAILURE IN WOMEN. Marian Limacher, MD Division of Cardiovascular Medicine University of Florida

Prevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient

ARIC Manuscript Proposal # PC Reviewed: 5/13/08 Status: A Priority: 2 SC Reviewed: Status: Priority:

The Diabetes Link to Heart Disease

Preventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex

Heart Failure and COPD: Common Partners, Common Problems. Nat Hawkins Liverpool Heart and Chest Hospital

Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension)

Blood Pressure Targets in Diabetes

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS

Clinical Recommendations: Patients with Periodontitis

2/11/2017. Weighing the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox. Disclosures. Carl J. Lavie, MD, FACC, FACP, FCCP

Measuring Quality and Performance in Treatment of Heart Failure in African-American Patients: V-HeFT and the Road to A-HeFT Peter Carson M.D.

Data Fact Sheet. Congestive Heart Failure in the United States: A New Epidemic

Review of guidelines for management of dyslipidemia in diabetic patients

New Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine

When should you treat blood pressure in the young?

Hypertension Update Clinical Controversies Regarding Age and Race

Statistical Fact Sheet Populations

Treating Heart Failure in Biodiverse Patient Populations: Best Practices and Unveiling Disparities in Blacks

Awareness of Hypertension, Risk Factors and Complications among Attendants of a Primary Health Care Center In Jeddah, Saudi Arabia

Gender Differences in Physical Inactivity and Cardiac Events in Men and Women with Type 2 Diabetes

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University

Health Benefits of Lowering Sodium Intake in the US

Randomized Design of ALLHAT BP Trial

Hypertension Update Background

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Hypertension Management Controversies in the Elderly Patient

Causes of Poor BP control Rates

Kathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School

The Impact of Smoking on Acute Ischemic Stroke

Hypertension Update. Aaron J. Friedberg, MD

ARIC Manuscript Proposal # 1618

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

Chapter 4: Cardiovascular Disease in Patients With CKD

ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study

Diversity and HTN: Approaches to optimal BP control in AfricanAmericans

Hypertension Update 2009

Hypertension and the SPRINT Trial: Is Lower Better

DECLARATION OF CONFLICT OF INTEREST

ORIGINAL INVESTIGATION. Effects of Prehypertension on Admissions and Deaths

University of Padova, Padua, Italy, and HARVEST Study Group, Italy

HCHS/SOL Submission Instructions for Manuscripts or Publications

Chronic Benefit Application Form Cardiovascular Disease and Diabetes

Association between arterial stiffness and cardiovascular risk factors in a pediatric population

Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database

The Metabolic Syndrome: Is It A Valid Concept? YES

Measure Owner Designation. AMA-PCPI is the measure owner. NCQA is the measure owner. QIP/CMS is the measure owner. AMA-NCQA is the measure owner

ARIC Manuscript Proposal #992. PC Reviewed: 01/20/04 Status: A Priority: 2 SC Reviewed: 01/20/04 Status: A Priority: 2

Heart Rate in Patients with Coronary Artery Disease - the Lower the Better? An Analysis from the Treating to New Targets (TNT) trial

Analytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?

Objectives. Heart failure and Hypertension. Definition & epidemiology of heart failure HEART FAILURE 3/12/2016. Kirsten Bibbins-Domingo, PhD, MD, MAS

Heart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre

Update on Current Trends in Hypertension Management

Socioeconomic status and the 25x25 risk factors as determinants of premature mortality: a multicohort study of 1.7 million men and women

Prevalence of anemia and cardiovascular diseases in chronic kidney disease patients: a single tertiary care centre study

CHAPTER 3 DIABETES MELLITUS, OBESITY, HYPERTENSION AND DYSLIPIDEMIA IN ADULT CENTRAL KERALA POPULATION

Supplementary Appendix

The Clinical Unmet need in the patient with Diabetes and ACS

Osama Sanad (MD) Prof. of Cardiology Benha University 2016

CONTRIBUTING FACTORS FOR STROKE:

HYPERTENSION AND HEART FAILURE

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)

The target blood pressure in patients with diabetes is <130 mm Hg

ORIGINAL INVESTIGATION. Risk Factors for Congestive Heart Failure in US Men and Women

CVD risk assessment using risk scores in primary and secondary prevention

Transcription:

ARIC Manuscript Proposal # 1475 PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: 1.a. Full Title: Hypertension, left ventricular hypertrophy, and risk of incident hospitalized heart failure: The ARIC study b. Abbreviated Title (Length 26 characters): Hypertension, LVH, and Heart failure 2. Writing Group: Writing group members: Patricia Chang Sunil K. Agarwal Aaron Folsom Ervin Fox Laura Loehr Edgar Miller Hanyu Ni Wayne Rosamond Herman Taylor (response awaited) I, the first author, confirm that all the coauthors have given their approval for this manuscript proposal. PC [please confirm with your initials electronically or in writing] I. First author: Patricia Chang Address: 101 Dental Circle, 6th Floor Burnett-Womack Bldg, Suite 6014, Mail Station 8030, Chapel Hill, NC, 27514-4145, Phone: (919) 843-5214 Fax: (919) 962-3265 E-mail: patricia_chang@med.unc.edu ARIC author to be contacted if there are questions about the manuscript and the first author does not respond or cannot be located (this must be an ARIC investigator). II. Name: Gerardo Heiss Phone: (919) 962-3253 Fax: (919) 966-9800 E-mail: gerardo_heiss@unc.edu 3. Timeline: Following approval of this manuscript by the ARIC Publications Committee this work will lead to manuscript(s) within 15 months.

4. Rationale: Heart Failure (HF) is a major public health problem in the US [1]. While it has a grim prognosis (30% mortality at one year)[2], HF treatment costs exceed those for both coronary artery disease and cancer combined and require about 5.4% of the total US health care cost [3]. Hypertension (HTN), a common HF precursor, is even more common, affecting 1 in 3 adults in the U.S., and more prevalent with an earlier onset among African Americans [4], Despite the well known association between HTN and coronary artery disease (CAD), few population based studies have shown an association between HTN and incident HF [5-8]. High blood pressure (BP) is strongly associated with CAD[4]. Also, high BP is associated with incident HF among patients with CAD [9]. However, high blood pressure may also have direct effect on myocardium, apart from its role in atherosclerosis and CAD. In large inpatient databases, systolic blood pressure was an independent predictor of morbidity and mortality in patients with HF, even those preserved systolic function[10]. Further, a recent analysis from the Framingham cohort showed that antecedent blood pressure and body mass index (BMI) were associated with incident HF despite adjustment for recent BP and BMI[11]. Also, patients who have HF with preserved ejection fraction (HFpEF or diastolic HF) tend to be older, female, and have a history of HTN [12]. These findings point to long-term cumulative adverse effects of high blood pressure on the heart. Left ventricular hypertrophy (LVH) is an adverse consequence of long-term high blood pressure and may lead to diastolic dysfunction and then HF. Interestingly, reduction in LVH (defined electrocardiographically by the Cornell criteria) during antihypertensive therapy is associated with fewer hospitalizations for HF, independent of blood pressure lowering, treatment method, and other risk factors for HF[13]. To date little (if any) information of this kind is available for African Americans, a population group that manifests a heavy burden of HF and its associated mortality. The ARIC cohort provides a unique opportunity to further understand more about the relationships between systolic and diastolic blood pressure, pulse pressure, left ventricular hypertrophy, and incident hospitalized heart failure among both blacks and whites. This cohort will provide opportunity to study the above relations in a CAD-free sub-cohort. 5. Main Hypothesis/Study Questions: 1. High blood pressure, as defined below, is associated with incident hospitalized HF among both blacks and white in the ARIC cohort. Hypertension will be defined using JNC VII criteria[14]. This will include isolated systolic hypertension (based on measured systolic blood pressure) and isolated diastolic hypertension (based on measured diastolic blood pressure). Uncontrolled hypertension will be defined as either SBP 140 mm Hg or DBP 90 mm Hg in participants answering yes to questions of selfreported hypertension and/or previous treatment of hypertension. 2. The association in 1 will exist even among those without prevalent or incident coronary heart disease. The association in the CHD-free sub-cohort will be

stronger among those who are older, obese, or have renal impairment as these factors are more strongly linked with diastolic dysfunction. 3. Left ventricular mass, as defined below, will be associated with incident hospitalized HF independent of measured blood pressure at baseline. Cornell voltage determined left ventricular hypertrophy (>32 mv in men, >28 mm in women) ECG determined continuous Cornell voltage 6. Design and analysis (study design, inclusion/exclusion, outcome and other variables of interest with specific reference to the time of their collection, summary of data analysis, and any anticipated methodologic limitations or challenges if present). Those with prevalent HF at baseline will be excluded for the main analysis. Prevalent HF is defined as the reported current intake of HF medication at the baseline examination (n = 83) or evidence of manifest HF as defined by the Gothenburg criteria stage 3 (n = 669), which require the presence of specific cardiac and pulmonary symptoms as well as medical treatment of HF[15]. In addition, 289 will be excluded due to the missing criteria needed to define prevalent HF. Incident HF was defined as the first HF hospitalization or HF coded as the underlying cause of death, identified through hospital records provided by all hospitals in the ARIC study areas and from death certificate codes from annual listings from state vital records offices. Hospitalizations were coded as heart failure (428) using the International Classification of Diseases Code, Ninth Revision (ICD-9), and deaths were coded as HF (428 and I50) using the ICD-9 and ICD-10. By January 1 st, 2003, 1193 study participants met these incident HF criteria. Analyses for this study will include additional incident HF events i.e., through 2005 using the same criteria. Cox proportional hazards regression models will be used to assess the hypotheses. For subset analysis involving a CAD-free cohort, individuals with baseline or incident CHD prior to incident CHF will be excluded. Proportional hazard assumptions will be examined for the main exposure and all covariates with log log curves and time interaction terms (Cox test). Linearity of log (HR) will be examined. We will examine statistical interaction in hazard ratios with age, gender, race, BMI, and renal dysfunction. In addition, since high blood pressure and other potential risk factors for HF (such as coronary artery disease, diabetes, obesity) can develop over time, secondary analyses will incorporate the exposure variables as time-varying in Cox proportional hazards models. Lastly, we will estimate the population attributable fraction of heart failure due to hypertension. Variables requested: Visit 1: Blood pressure measures, medication, demographics (age, gender, race, center), Socio economic indicators (education and income), anthropometric measures (height, BMI, waist circumference, waist-hip ratio), comorbidites and CVD risk factors

(smoking, COPD, T2DM, hypertension, LDL-cholesterol, HDL cholesterol), Gothenburg score, prevalent CAD. Visit 2 to visit 4: Blood pressure measurements, medication use, LDL cholesterol, HDL cholesterol, fasting blood sugar, T2DM, BMI, smoking status Follow up through 2005: incident CHD, incident hospitalized HF 7.a. Will the data be used for non-cvd analysis in this manuscript? No 8.a. Will the DNA data be used in this manuscript? No 9. The lead author of this manuscript proposal has reviewed the list of existing ARIC Study manuscript proposals and has found no overlap between this proposal and previously approved manuscript proposals either published or still in active status. There is slight overlap with a sub-aim of existing proposal MP#1342 (The preventable burden of heart failure due to obesity and hypertension). While MP#1342 will try to estimate an attributable fraction due to clinically defined hypertension, this proposal will examine a causal association of hypertension and left ventricular hypertrophy with heart failure. The lead author (Laura Loehr) is a coauthor of this proposal and has agreed with this proposal. 10. What are the most related manuscript proposals in ARIC (authors are encouraged to contact lead authors of these proposals for comments on the new proposal or collaboration)? MP#1342 The preventable burden of heart failure due to obesity and hypertension. (Please see above) There are other proposals looking at other risk factors of heart failure as listed below. These proposals include hypertension as a potential confounder in their multivariable models but are not otherwise focused on hypertension as a risk factor for heart failure. MP#922 Alcohol consumption and risk of congestive heart failure MP#890B Plasma Fatty Acid Composition and Incidence of Heart Failure in Middle Aged Adults MP#1118 Kidney Function as a Risk Factor for Incident Heart Failure MP#1125 Diabetes, obesity and insulin resistance as risk factors for incident hospitalized HF MP#1144 The Obesity Paradox in Heart Failure. MP#1160 Life Course Socioeconomic Exposures and Heart Failure. MP# 1164 Hemoglobin A1c as a Risk Factor for HF Hospitalization among Persons with Diabetes. MP#1197 Albuminuria as a Predictor of Incident Heart Failure Hospitalization and Mortality.

MP#1232 ECG Abnormalities Preceding Heart Failure: Estimation and Prediction MP#1276 Exhaustion and risk for congestive heart failure. MP#1377 Relationship between pulmonary disease, lung function and incident hospitalized heart failure 11. a. Is this manuscript proposal associated with any ARIC ancillary studies or use any ancillary study data? No 12. The authors are aware of proposal expiration at three years, if incomplete. References 1. Garg, R., et al., Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine. J Am Coll Cardiol, 1993. 22(4 Suppl A): p. 3A-5A. 2. Levy, D., et al., Long-term trends in the incidence of and survival with heart failure. N Engl J Med, 2002. 347(18): p. 1397-402. 3. O'Connell, J.B. and M.R. Bristow, Economic impact of heart failure in the United States: time for a different approach. 1994. p. S107-12. 4. Rosamond, W., et al., Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2008. 117(4): p. e25-146. 5. Ingelsson, E., et al., Socioeconomic factors as predictors of incident heart failure. J Card Fail, 2006. 12(7): p. 540-5. 6. Haider, A.W., et al., Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med, 2003. 138(1): p. 10-6. 7. Bener, A., et al., The effect of hypertension as a predictor of risk for congestive heart failure patients over a 10-year period in a newly developed country. Blood Press, 2004. 13(1): p. 41-6. 8. Peyster, E., J. Norman, and M. Domanski, Prevalence and predictors of heart failure with preserved systolic function: community hospital admissions of a racially and gender diverse elderly population. J Card Fail, 2004. 10(1): p. 49-54. 9. Bibbins-Domingo, K., et al., Predictors of heart failure among women with coronary disease. Circulation, 2004. 110(11): p. 1424-30. 10. Gheorghiade, M., et al., Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. Jama, 2006. 296(18): p. 2217-26. 11. Lee, D.S., et al., Antecedent blood pressure, body mass index, and the risk of incident heart failure in later life. Hypertension, 2007. 50(5): p. 869-76. 12. Jessup, M. and S. Brozena, Heart failure. N Engl J Med, 2003. 348(20): p. 2007-18. 13. Okin, P.M., et al., Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann Intern Med, 2007. 147(5): p. 311-9. 14. Chobanian, A.V., et al., The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA, 2003. 289(19): p. 2560-72. 15. Eriksson, H., et al., Cardiac and pulmonary causes of dyspnoea--validation of a scoring test for clinical-epidemiological use: the Study of Men Born in 1913. Eur Heart J, 1987. 8(9): p. 1007-14.